Article in International journal of molecular sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.7field-weighted citation impact, top 28% of its field
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
2 citing papers in PubMed, 3 citations in OpenAlex.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
16 authors at 5 institutions in 3 countries.
Lutfi A HasnowoSchool of Nuclear Science and Engineering, Tomsk Polytechnic University, Tomsk 634050, Russia.ORCID 0000-0001-5614-9603
Maria S LarkinaResearch Centrum for Oncotheranostics, Research School of Chemistry and Applied Biomedical Sciences, Tomsk Polytechnic University, Tomsk 634050, Russia.
Evgenii PlotnikovResearch Centrum for Oncotheranostics, Research School of Chemistry and Applied Biomedical Sciences, Tomsk Polytechnic University, Tomsk 634050, Russia.ORCID 0000-0002-4374-6422
Vitalina BodenkoResearch Centrum for Oncotheranostics, Research School of Chemistry and Applied Biomedical Sciences, Tomsk Polytechnic University, Tomsk 634050, Russia.
Feruza YuldashevaResearch Centrum for Oncotheranostics, Research School of Chemistry and Applied Biomedical Sciences, Tomsk Polytechnic University, Tomsk 634050, Russia.
Elena StasyukSchool of Nuclear Science and Engineering, Tomsk Polytechnic University, Tomsk 634050, Russia.
Stanislav A PetrovDepartment of Chemistry, M.V. Lomonosov Moscow State University Leninskie Gory, 1-3, Moscow 119991, Russia.ORCID 0000-0002-6000-6100
Nikolai Y ZykDepartment of Chemistry, M.V. Lomonosov Moscow State University Leninskie Gory, 1-3, Moscow 119991, Russia.ORCID 0000-0002-5302-9160
Aleksei E MachulkinDepartment of Chemistry, M.V. Lomonosov Moscow State University Leninskie Gory, 1-3, Moscow 119991, Russia.ORCID 0000-0001-7975-0346
Nikolai I VorozhtsovDepartment of Chemistry, M.V. Lomonosov Moscow State University Leninskie Gory, 1-3, Moscow 119991, Russia.
Elena K BeloglazkinaDepartment of Chemistry, M.V. Lomonosov Moscow State University Leninskie Gory, 1-3, Moscow 119991, Russia.ORCID 0000-0001-6796-8241
Valentine G NenajdenkoDepartment of Chemistry, M.V. Lomonosov Moscow State University Leninskie Gory, 1-3, Moscow 119991, Russia.ORCID 0000-0001-9162-5169
Vladimir TolmachevDepartment of Immunology, Genetics and Pathology, Uppsala University, 75185 Uppsala, Sweden.ORCID 0000-0002-6122-1734
Anna OrlovaDepartment of Medicinal Chemistry, Uppsala University, 75183 Uppsala, Sweden.ORCID 0000-0001-6120-2683
Alexander G MajougaFaculty of Chemistry, Dmitry Mendeleev University of Chemical Technology of Russia, Miusskaya sq. 9, Moscow 125047, Russia.
Mekhman S YusubovResearch Centrum for Oncotheranostics, Research School of Chemistry and Applied Biomedical Sciences, Tomsk Polytechnic University, Tomsk 634050, Russia.
Lomonosov Moscow State University · RUNational Research Tomsk State University · RUUppsala University · SED. Mendeleyev University of Chemical Technology of Russia · RURussian Academy of Sciences · RU
Funding
President of the Russian Federation MK-3748.2022.1.3Russian Science Foundation 22-15-00098, https://rscf.ru/project/22-15-00098/ (Synthesis of PSMA ligands)Russian Science Foundation No: 21-13-00023TPU development program Priority 2030 Priority-2030-NIP/IS-042-375-2023
6 · The paper itself
Abstract
Prostate-specific membrane antigen (PSMA) has been identified as a target for the development of theranostic agents. In our current work, we describe the design and synthesis of novel N-[N-[(S)-1,3-dicarboxypropyl]carbamoyl]-(S)-L-lysine (DCL) urea-based PSMA inhibitors with a chlorine-substituted aromatic fragment at the lysine ε-nitrogen atom, a dipeptide including two phenylalanine residues in the L-configuration as the peptide fragment of the linker, and 3- or 4-(tributylstannyl)benzoic acid as a prosthetic group in their structures for radiolabeling. The standard compounds [
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.